Schrodinger, Inc. (SDGR) shareholders
SDGRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3070% above fair value
$29.53−1.32 (-4.28%)
Close on Nov 13, 2026Market cap $2.21BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
86.5%
65M of 75M shares
Institutional holders
231
46 new, 39 sold out
Net institutional buying
-1M
In Q2 2026
Insider trades, 12 months
0 buys · 26 sales
Net sold $4.15M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 8,164,484 | 12.70% | 13G (passive) amendment | Jun 30, 2025 |
| Rubric Capital Management LP Joint filing with David Rosen (9.28%) | 6,000,000 | 9.28% | 13G (passive) amendment | Mar 31, 2026 |
| David Rosen Joint filing with Rubric Capital Management LP (7.85%) | 5,000,000 | 7.85% | 13G (passive) amendment | Dec 31, 2024 |
| Amova Asset Management Co., Ltd. Joint filing with Sumitomo Mitsui Trust Group, Inc. (7.10%) | 4,554,569 | 7.10% | 13G (passive) amendment | Sep 30, 2025 |
| Vanguard Portfolio Management | 3,911,087 | 6.04% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SDGR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 10,521,724 | 14.07% | $170.98M | +843,164 | 0.00% |
| Bill & Melinda Gates Foundation Trust | 6,981,664 | 9.33% | $113.45M | – | 0.33% |
| Rubric Capital Management LP | 6,400,000 | 8.56% | $104.00M | +400,000 | 0.95% |
| Vanguard Portfolio Management LLC | 3,787,391 | 5.06% | $61.55M | −74,806 | 0.00% |
| Nikko Asset Management Americas, Inc. | 2,706,143 | 3.62% | $43.95M | −484,694 | 0.57% |
| Sumitomo Mitsui Trust Holdings, Inc. | 2,706,143 | 3.62% | $43.97M | −484,694 | 0.03% |
| Vanguard Capital Management LLC | 2,691,149 | 3.60% | $43.73M | +86,775 | 0.00% |
| State Street Corp | 2,298,338 | 3.07% | $37.35M | +106,911 | 0.00% |
| UBS Asset Management Americas Inc | 2,221,485 | 2.97% | $36.10M | −438,798 | 0.01% |
| ARK Investment Management LLC | 2,154,018 | 2.88% | $35.00M | +86,883 | 0.23% |
| Aqr Capital Management LLC | 1,956,347 | 2.62% | $31.79M | +1,512,189 | 0.01% |
| Geode Capital Management, LLC | 1,471,182 | 1.97% | $23.91M | +119,686 | 0.00% |
| Morgan Stanley | 1,245,015 | 1.66% | $20.23M | −126,184 | 0.00% |
| UBS Group AG | 964,129 | 1.29% | $15.67M | −355,923 | 0.00% |
| Citadel Advisors LLC | 895,780 | 1.20% | $14.56M | +698,533 | 0.00% |
| Massachusetts Financial Services Co /Ma/ | 866,942 | 1.16% | $14.09M | −1,817,750 | 0.00% |
| Goldman Sachs Group Inc | 732,904 | 0.98% | $11.91M | −19,719 | 0.00% |
| Northern Trust Corp | 649,519 | 0.87% | $10.55M | +76,376 | 0.00% |
| Dimensional Fund Advisors LP | 636,367 | 0.85% | $10.35M | −247,281 | 0.00% |
| Nuveen, LLC | 614,314 | 0.82% | $9.98M | +488,474 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 231 | 65M | 86.5% | 46 / 82 | 63 / 39 | 8M | 9M |
| Q1 2026 | 228 | 66M | 88.0% | 50 / 82 | 57 / 41 | 15M | 12M |
| Q4 2025 | 223 | 70M | 93.1% | 27 / 77 | 80 / 29 | 5M | 5M |
| Q3 2025 | 225 | 70M | 93.2% | 27 / 64 | 96 / 35 | 7M | 9M |
| Q2 2025 | 233 | 71M | 95.3% | 44 / 80 | 78 / 27 | 11M | 6M |
| Q1 2025 | 218 | 66M | 88.5% | 31 / 76 | 68 / 22 | 8M | 3M |
| Q4 2024 | 212 | 62M | 82.7% | 33 / 64 | 78 / 27 | 6M | 5M |
| Q3 2024 | 208 | 60M | 80.8% | 33 / 65 | 73 / 31 | 13M | 3M |
| Q2 2024 | 207 | 60M | 79.9% | 28 / 71 | 67 / 43 | 8M | 9M |
| Q1 2024 | 223 | 62M | 83.1% | 29 / 74 | 72 / 43 | 8M | 5M |
| Q4 2023 | 239 | 59M | 79.1% | 44 / 82 | 75 / 39 | 7M | 4M |
| Q3 2023 | 235 | 56M | 75.3% | 41 / 79 | 81 / 42 | 4M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
191 funds held SDGR in Q2 2026, 72% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of SDGR | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 3,436,925 | 4.59% | $55.85M | 0.05% | Jun 30, 2026 |
| ARK Genomic Revolution ETF | 2,042,579 | 2.73% | $30.92M | 1.99% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,965,067 | 2.63% | $31.93M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,486,164 | 1.99% | $24.15M | 0.03% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,426,780 | 1.91% | $23.19M | 0.01% | Jun 30, 2026 |
| MFS New Discovery Fund | 1,213,659 | 1.62% | $18.45M | 0.86% | May 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 834,782 | 1.12% | $13.57M | 0.03% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 662,066 | 0.89% | $10.76M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 632,265 | 0.85% | $9.57M | 0.03% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 543,735 | 0.73% | $8.84M | 0.06% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 521,310 | 0.70% | $8.47M | 0.05% | Jun 30, 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 510,010 | 0.68% | $8.29M | 0.10% | Jun 30, 2026 |
| State Street(R) SPDR(R) S & P 600(TM) Small Cap Growth ETF | 313,864 | 0.42% | $5.10M | 0.10% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 303,405 | 0.41% | $4.61M | 0.01% | May 31, 2026 |
| BlackRock Advantage Small Cap Core Fund | 293,460 | 0.39% | $4.46M | 0.08% | May 29, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ramy Farid | President & CEO, Director | 330,824 | 0.44% | Apr 17, 2026 |
| Paul Jonathan Davie | See Remarks | 18,400 | 0.02% | Nov 12, 2026 |
| Robert Lorne Abel | See Remarks | 54,219 | 0.07% | Nov 12, 2026 |
| Yvonne Tran | EVP, CLO & CPO | 52,683 | 0.07% | Nov 10, 2026 |
| Karen Akinsanya | See Remarks | 101,555 | 0.14% | Sep 21, 2026 |
| Rachit Jain | EVP & CFO | 50,877 | 0.07% | Jul 17, 2026 |
| Therese Marie Abrams | VP, Corporate Controller | 19,461 | 0.03% | Mar 19, 2026 |
| Kenneth Patrick Lorton | EVP, CTO & COO, Software | 89,241 | 0.12% | Mar 6, 2026 |
| Jenny Herman | CAO | 34,804 | 0.05% | Mar 6, 2026 |
| Mannix Vartan Aklian | See Remarks | 31,193 | 0.04% | Mar 3, 2026 |
| Margaret Dugan | Chief Medical Officer | 24,574 | 0.03% | Oct 17, 2025 |
| Geoffrey Craig Porges | EVP & CFO | 18,185 | 0.02% | Mar 4, 2025 |
| Richard Friesner | Director | 1,413,618 | 1.89% | Jun 29, 2026 |
| Rosana Kapeller-Libermann | Director | 25,388 | 0.03% | Jun 23, 2026 |
| Michael Lynton | Director | 25,388 | 0.03% | Jun 23, 2026 |
| Nancy Thornberry | Director | 25,388 | 0.03% | Jun 23, 2026 |
| Gary L. Ginsberg | Director | 25,388 | 0.03% | Jun 23, 2026 |
| Kralingen Bridget A. van | Director | 19,640 | 0.03% | Jun 23, 2026 |
| Jeffrey Chodakewitz | Director | 25,388 | 0.03% | Jun 23, 2026 |
| Gary Sender | Director | 25,388 | 0.03% | Jun 23, 2026 |
| Arun Oberoi | Director | 25,388 | 0.03% | Jun 23, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Paul Jonathan Davie See Remarks | Nov 11, 2026 | Award | +18,400 | – | – | 18,400 |
| Robert Lorne Abel See Remarks | Nov 11, 2026 | Sale(10b5-1 plan) | −1,678 | $34.00 | $57.05K | 54,219 |
| Robert Lorne Abel See Remarks | Nov 11, 2026 | Sale(10b5-1 plan) | −21,927 | $34.00 | $745.52K | 55,897 |
| Robert Lorne Abel See Remarks | Nov 11, 2026 | Option exercise | +21,927 | $17.00 | $372.76K | 77,824 |
| Yvonne Tran EVP, CLO & CPO | Nov 9, 2026 | Sale(10b5-1 plan) | −21,599 | $33.11 | $715.19K | 52,683 |
| Yvonne Tran EVP, CLO & CPO | Nov 9, 2026 | Sale(10b5-1 plan) | −7,901 | $32.64 | $257.90K | 74,282 |
| Yvonne Tran EVP, CLO & CPO | Nov 9, 2026 | Sale(10b5-1 plan) | −2,100 | $31.45 | $66.05K | 82,183 |
| Yvonne Tran EVP, CLO & CPO | Nov 9, 2026 | Sale(10b5-1 plan) | −400 | $29.97 | $11.99K | 84,283 |
| Yvonne Tran EVP, CLO & CPO | Nov 9, 2026 | Option exercise | +32,000 | $17.00 | $544.00K | 84,683 |
| Karen Akinsanya See Remarks | Sep 17, 2026 | Option exercise | +31,599 | $4.34 | $137.14K | 101,555 |
| Karen Akinsanya See Remarks | Sep 17, 2026 | Sale(10b5-1 plan) | −21,599 | $30.00 | $647.97K | 69,956 |
| Karen Akinsanya See Remarks | Sep 17, 2026 | Sale(10b5-1 plan) | −10,000 | $28.00 | $280.00K | 91,555 |
| Rachit Jain EVP & CFO | Jul 16, 2026 | Sale(10b5-1 plan) | −875 | $15.60 | $13.65K | 50,877 |
| Richard Friesner Director | Jun 26, 2026 | Gift | +679,373 | – | – | 679,373 |
| Richard Friesner Director | Jun 26, 2026 | Gift | −679,373 | – | – | 0 |
| Kralingen Bridget A. van Director | Jun 22, 2026 | Award | +8,141 | – | – | 19,640 |
| Gary Sender Director | Jun 22, 2026 | Award | +8,141 | – | – | 25,388 |
| Rosana Kapeller-Libermann Director | Jun 22, 2026 | Award | +8,141 | – | – | 25,388 |
| Richard Friesner Director | Jun 22, 2026 | Award | +8,141 | – | – | 690,365 |
| Nancy Thornberry Director | Jun 22, 2026 | Award | +8,141 | – | – | 25,388 |
| Jeffrey Chodakewitz Director | Jun 22, 2026 | Award | +8,141 | – | – | 25,388 |
| Arun Oberoi Director | Jun 22, 2026 | Award | +8,141 | – | – | 25,388 |
| Gary L. Ginsberg Director | Jun 22, 2026 | Award | +8,141 | – | – | 25,388 |
| Michael Lynton Director | Jun 22, 2026 | Award | +8,141 | – | – | 25,388 |
| Ramy Farid President & CEO, Director | Apr 17, 2026 | Sale(10b5-1 plan) | −43,000 | $12.21 | $525.03K | 330,824 |
| Ramy Farid President & CEO, Director | Apr 17, 2026 | Option exercise | +43,000 | $3.07 | $132.01K | 373,824 |
| Ramy Farid President & CEO, Director | Apr 17, 2026 | Option exercise | +74,527 | $3.07 | $228.80K | 405,351 |
| Rachit Jain EVP & CFO | Apr 16, 2026 | Sale(10b5-1 plan) | −844 | $12.75 | $10.76K | 51,752 |
| Ramy Farid President & CEO, Director | Apr 16, 2026 | Sale(10b5-1 plan) | −43,000 | $12.33 | $530.19K | 330,824 |
| Ramy Farid President & CEO, Director | Apr 16, 2026 | Option exercise | +43,000 | $3.07 | $132.01K | 373,824 |
| Jenny Herman CAO | Mar 6, 2026 | Sale(10b5-1 plan) | −608 | $12.84 | $7.81K | 34,804 |
| Kenneth Patrick Lorton EVP, CTO & COO, Software | Mar 5, 2026 | Sale(10b5-1 plan) | −1,222 | $12.90 | $15.76K | 89,241 |
| Yvonne Tran EVP, CLO & CPO | Mar 5, 2026 | Sale(10b5-1 plan) | −1,094 | $12.90 | $14.11K | 52,683 |
| Jenny Herman CAO | Mar 5, 2026 | Sale(10b5-1 plan) | −775 | $12.85 | $9.96K | 35,412 |
| Rachit Jain EVP & CFO | Mar 5, 2026 | Sale(10b5-1 plan) | −1,631 | $12.90 | $21.04K | 52,596 |
| Karen Akinsanya See Remarks | Mar 5, 2026 | Sale(10b5-1 plan) | −1,366 | $12.90 | $17.62K | 69,956 |
| Ramy Farid President & CEO, Director | Mar 5, 2026 | Sale(10b5-1 plan) | −3,661 | $12.91 | $47.26K | 330,824 |
| Robert Lorne Abel See Remarks | Mar 4, 2026 | Sale(10b5-1 plan) | −1,300 | $12.81 | $16.65K | 55,897 |
| Mannix Vartan Aklian See Remarks | Mar 2, 2026 | Award | +17,130 | – | – | 31,193 |
| Karen Akinsanya See Remarks | Mar 2, 2026 | Award | +6,077 | – | – | 45,952 |
| Karen Akinsanya See Remarks | Mar 2, 2026 | Award | +27,576 | – | – | 73,528 |
| Karen Akinsanya See Remarks | Mar 2, 2026 | Sale(10b5-1 plan) | −2,206 | $11.99 | $26.45K | 71,322 |
| Karen Akinsanya See Remarks | Mar 2, 2026 | Award | +24,250 | – | – | 39,875 |
| Yvonne Tran EVP, CLO & CPO | Mar 2, 2026 | Award | +13,788 | – | – | 53,777 |
| Yvonne Tran EVP, CLO & CPO | Mar 2, 2026 | Award | +17,130 | – | – | 39,989 |
| Ramy Farid President & CEO, Director | Mar 2, 2026 | Award | +13,604 | – | – | 291,786 |
| Ramy Farid President & CEO, Director | Mar 2, 2026 | Award | +48,259 | – | – | 340,045 |
| Ramy Farid President & CEO, Director | Mar 2, 2026 | Sale(10b5-1 plan) | −5,560 | $11.90 | $66.16K | 334,485 |
| Ramy Farid President & CEO, Director | Mar 2, 2026 | Award | +56,250 | – | – | 278,182 |
| Jenny Herman CAO | Mar 2, 2026 | Award | +9,590 | – | – | 36,187 |
| Kenneth Patrick Lorton EVP, CTO & COO, Software | Mar 2, 2026 | Award | +17,130 | – | – | 69,781 |
| Kenneth Patrick Lorton EVP, CTO & COO, Software | Mar 2, 2026 | Award | +20,682 | – | – | 90,463 |
| Richard Friesner Director | Mar 2, 2026 | Option exercise | +160,527 | $3.07 | $492.82K | 682,224 |
| Robert Lorne Abel See Remarks | Mar 2, 2026 | Award | +20,682 | – | – | 57,197 |
| Robert Lorne Abel See Remarks | Mar 2, 2026 | Award | +17,130 | – | – | 36,515 |
| Rachit Jain EVP & CFO | Mar 2, 2026 | Award | +17,130 | – | – | 54,227 |
| Yvonne Tran EVP, CLO & CPO | Feb 10, 2026 | Sale(10b5-1 plan) | −776 | $13.80 | $10.71K | 22,859 |
| Jenny Herman CAO | Feb 10, 2026 | Sale(10b5-1 plan) | −752 | $13.79 | $10.37K | 26,597 |
| Kenneth Patrick Lorton EVP, CTO & COO, Software | Feb 10, 2026 | Sale(10b5-1 plan) | −925 | $13.73 | $12.70K | 52,651 |
| Robert Lorne Abel See Remarks | Feb 9, 2026 | Sale(10b5-1 plan) | −1,230 | $13.51 | $16.62K | 19,385 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
13.47%
10M shares short
Days to cover
5.8
At 2M shares a day
Change since last report
-6.3%
From 10M shares
Short volume, 20 days
49.8%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Schrodinger's stock actually held short. Settlement fails (shares not delivered on time) peaked at 26,773 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Yvonne Tran Officer | Nov 9, 2026 | 32,000 | $954.24K | Nov 9, 2026 | Exercise of Stock Options |
| Karen Olufunmilyo Akinsanya-Akiwumi Officer | Sep 17, 2026 | 31,599 | $756.16K | Sep 17, 2026 | Exercise of Stock Options |
| Rachit Jain Officer | Jul 16, 2026 | 875 | $13.65K | Jul 16, 2026 | Restricted Stock Vesting |
| Mannix Vartan Aklian Officer | Jul 1, 2026 | 1,136 | $18.95K | Jul 1, 2026 | Restricted Stock Vesting |
| Jenny Herman Officer | May 1, 2026 | 1,957 | $24.00K | May 1, 2026 | Restricted Stock Vesting |
| Rachit Jain Officer | Apr 16, 2026 | 844 | $10.76K | Apr 16, 2026 | Restricted Stock Vesting |
| Ramy Farid Director, Officer | Apr 16, 2026 | 86,000 | $1.07M | Apr 16, 2026 | Exercise of Stock Options |
| Jenny Herman Officer | Mar 6, 2026 | 608 | $7.81K | Mar 6, 2026 | Restricted Stock Vesting |
| Karen Akinsanya Officer | Mar 5, 2026 | 1,366 | $17.63K | Mar 5, 2026 | Restricted Stock Vesting |
| Rachit Jain Officer | Mar 5, 2026 | 1,631 | $21.03K | Mar 5, 2026 | Restricted Stock Vesting |
| Ramy Farid Officer, Director | Mar 5, 2026 | 3,661 | $47.25K | Mar 5, 2026 | Restricted Stock Vesting |
| Jenny Herman Officer | Mar 5, 2026 | 775 | $9.96K | Mar 5, 2026 | Restricted Stock Vesting |
| Kenneth Patrick Lorton Officer | Mar 5, 2026 | 1,222 | $15.76K | Mar 5, 2026 | Restricted Stock Vesting |
| Yvonne Tran Officer | Mar 5, 2026 | 1,094 | $14.11K | Mar 5, 2026 | Restricted Stock Vesting |
| Robert Lorne Abel Officer | Mar 4, 2026 | 1,300 | $16.55K | Mar 4, 2026 | Stock Bonus |
See a number that looks wrong?